Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept

Weinberg, J.M.; Saini, R.; Tutrone, W.D.

Journal of Drugs in Dermatology Jdd 1(3): 303-310

2002

ISSN/ISBN: 1545-9616
PMID: 12851990
Document Number: 8375
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.

Document emailed within 1 workday
Secure & encrypted payments

Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept

Weinberg, J.M.; Bottino, C.J.; Lindholm, J.; Buchholz, R. 2005: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept Journal of Drugs in Dermatology: Jdd 4(5): 544-555
Tutrone, W.D.; Saini, R.; Weinberg, J.M. 2004: Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept Idrugs: the Investigational Drugs Journal 7(1): 45-49
Weinberg, J.M.; Saini, R. 2003: Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept Cutis 71(1): 25-29
Kalb, R.E.; Blauvelt, A.; Sofen, H.L.; Chevrier, M.; Amato, D.; Calabro, S.; Wang, J.; Schenkel, B.; Gottlieb, A.B. 2013: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial Journal of Drugs in Dermatology: Jdd 12(8): 874-880
Fretzin, S.; Crowley, J.; Jones, L.; Young, M.; Sobell, J. 2006: Successful treatment of hand and foot psoriasis with efalizumab therapy Journal of Drugs in Dermatology: Jdd 5(9): 838-846
Strober, B.E.; Clarke, S. 2004: Etanercept for the treatment of psoriasis: combination therapy with other modalities Journal of Drugs in Dermatology: Jdd 3(3): 270-272
Gottlieb, A.B.; Gordon, K.B.; Lebwohl, M.G.; Caro, I.; Walicke, P.A.; Li, N.; Leonardi, C.L. 2004: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis Journal of Drugs in Dermatology: Jdd 3(6): 614-624
Lui, H.; Gulliver, W.; Tan, J.; Hong, C-Ho.; Hull, P.; Shear, N.H.; Paradiso-Hardy, F.; Bissonette, R. 2012: A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response Journal of Drugs in Dermatology: Jdd 11(8): 929-937
Kamili, Q.U.A.; Miner, A.; Hapa, A.; Menter, A. 2011: Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review Journal of Drugs in Dermatology: Jdd 10(5): 539-544
Mahiques Santos, L.; Martínez Menchón, T.; Sánchez Carazo, Jé.Luis.; Fortea Baixauli, Jé.Miguel. 2005: Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy Medicina Clinica 125(4): 159
Tutrone, W.D.; Kagen, M.H.; Barbagallo, J.; Weinberg, J.M. 2001: Biologic therapy for psoriasis: a brief history, i Cutis 68(5): 331-336
Farnsworth, N.N.; George, S.J.; Hsu, S. 2005: Successful use of infliximab following a failed course of etanercept in a pediatric patient Dermatology Online Journal 11(3): 11
Potenza, C.; Raimondi, G.; Pampena, R.; Bernardini, N.; La Viola, G.; Tolino, E.; Zuber, S.; Scordamaglia, B.; Skroza, N. 2016: Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) Analysis in Patients with Psoriasis before and after 12 Weeks of Etanercept Therapy: a Preliminary Prospective Study Acta Dermatovenerologica Croatica: Adc 24(3): 181-186
Gordon, K.B.; Langley, R.G. 2003: Remittive effects of intramuscular alefacept in psoriasis Journal of Drugs in Dermatology: Jdd 2(6): 624-628
Cancelliere, N.; Barranco, P.; Vidaurrázaga, C.; Benito, D.-M.; Quirce, S. 2011: Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept Journal of Investigational Allergology and Clinical Immunology 21(3): 248-249
George, D.; Rosen, T. 2009: Treatment of inverse psoriasis with efalizumab Journal of Drugs in Dermatology: Jdd 8(1): 74-76
Golda, N.; Benham, S.M.; Koo, J. 2006: Rebound of psoriasis during treatment with efalizumab Journal of Drugs in Dermatology: Jdd 5(1): 63-65
Skroza, N.; Proietti, I.; Bernardini, N.; La Viola, G.; Nicolucci, F.; Tolino, E.; Zuber, S.; Potenza, C. 2012: Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report Cutis 90(3): 120-122
Bissonnette, R.; Kerdel, F.; Naldi, L.; Papp, K.; Galindo, C.; Langholff, W.; Tang, K.L.; Szapary, P.; Fakharzadeh, S.; Srivastava, B.; Goyal, K.; Gottlieb, A.B. 2017: Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis Journal of Drugs in Dermatology: Jdd 16(10): 1002-1013
Gaylor, M.-L.N.; Duvic, M. 2004: Generalized pustular psoriasis following withdrawal of efalizumab Journal of Drugs in Dermatology: Jdd 3(1): 77-79